AGIOS PHARMACEUTICALS, INC. (AGIO)

Current Report Filed: 2026-04-29

Agios announced Q1 2026 financial results on April 29, 2026, providing investors with quarterly performance metrics and business updates through an earnings press release.
The 8-K filing itself contains minimal substantive financial data, with actual results and highlights deferred to the press release exhibit, limiting immediate transparency without reviewing the full disclosure document.
CEO Brian Goff signed the filing, confirming executive accountability for the reported results and any forward-looking statements regarding the company's pipeline and strategic direction.

Quarterly Report Filed: 2026-04-29

The filing appears to be a routine Q1 2026 10-Q submission with standard XBRL data structure, containing product revenue data and equity accounting information but lacking specific financial metrics in the provided excerpt.
Notable data points include tracking of Vorasidenib product performance with contingent payments and royalty rights dated May 2024, suggesting ongoing commercialization of a key pipeline asset.
The filing documents fair value measurements of investment securities across multiple levels (Level 1-3), indicating active management of cash and investment portfolio during the quarter.

Insider Trading Filed: 2026-04-06

Insider Brian Goff, the CEO, exercised performance share units and sold a portion of the shares to cover tax withholding, indicating a transaction under a pre-established 10b5-1 trading plan.
The vesting of performance share units was triggered by the achievement of regulatory milestones, suggesting progress in the company's clinical development pipeline.
The timing and amount of shares sold by the CEO suggest a measured approach to managing his equity position, which could be viewed positively by investors.

Insider Trading Filed: 2026-04-06

Insider Krishnan Viswanadhan, the Chief Corp Dev & Strategy officer, exercised 8,100 performance share units and sold 2,959 shares to cover tax withholding obligations, indicating some insider liquidity but still retaining a direct ownership of 10,282 shares.
The vesting of the performance share units was tied to the achievement of a specified regulatory milestone, suggesting progress in the company's regulatory efforts.
The share sale was made pursuant to a 10b5-1 trading plan, providing an affirmative defense against insider trading liability and indicating a predetermined, non-discretionary transaction.

Insider Trading Filed: 2026-04-06

The reporting person, Tsveta Milanova, is the Chief Commercial Officer of Agios Pharmaceuticals, Inc. (AGIO), indicating a key insider transaction.
Milanova acquired 8,500 shares of AGIO common stock through the vesting of performance share units (PSUs), and subsequently sold 3,262 shares to cover tax withholding obligations.
The PSUs vested based on the achievement of a specified regulatory milestone, suggesting progress in the company's product development pipeline.

Insider Trading Filed: 2026-04-06

Cecilia Jones, the Chief Financial Officer of Agios Pharmaceuticals, exercised 8,500 performance share units and sold 3,141 shares to cover tax withholding obligations. This suggests ongoing insider confidence and alignment with shareholder interests.
The vesting of the performance share units was tied to the achievement of specified regulatory and commercial milestones, indicating the company is making progress on its key development programs.
The sale of shares to cover tax withholding was executed pursuant to a pre-established 10b5-1 trading plan, which provides a level of transparency and reduces the risk of insider trading allegations.

Insider Trading Filed: 2026-04-06

Sarah Gheuens, the Chief Medical Officer, exercised 8,500 performance share units (PSUs) and sold 2,940 shares to cover the tax withholding obligations, indicating an ongoing alignment of her interests with those of the company and shareholders.
The vesting of the PSUs was tied to the achievement of specified regulatory and commercial milestones, suggesting progress in the company's pipeline and commercialization efforts.
The share sale was executed pursuant to a 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations and demonstrates a disciplined approach to managing insider transactions.

Insider Trading Filed: 2026-04-06

Insider James William Burns, the Chief Legal Officer, exercised 8,500 performance share units (PSUs) and sold 3,280 shares to cover tax withholding obligations, suggesting he remains confident in the company's future performance.
The vesting of the PSUs was tied to the achievement of regulatory and commercial milestones, indicating the company has made progress in advancing its pipeline.
The sale of a portion of the shares to cover taxes suggests Burns is not looking to significantly reduce his overall stake in the company, maintaining his alignment with shareholders.

Insider Trading Filed: 2026-03-09

Krishnan Viswanadhan, the Chief Corporate Development and Strategy Officer of Agios Pharmaceuticals, Inc. (AGIO), exercised 8,100 restricted stock units and sold 2,959 shares to cover tax withholding obligations, indicating ongoing executive confidence in the company.
The timing of the transaction, in early March 2026, suggests the reporting person is aligning their holdings with the company's vesting schedule and potentially maintaining a consistent stake in the business.
The sale of a portion of the shares to cover taxes is a common practice and does not necessarily signal a broader divestment, as the reporting person still holds a direct ownership of 5,141 common shares.

Current Report Filed: 2026-01-12

Agios Pharmaceuticals announced anticipated milestones for 2026, indicating potential progress in its drug development pipeline.
The company will present the 2026 milestones at the 44th Annual J.P. Morgan Healthcare Conference, providing investors with an update on the company's strategic priorities.
The filing provides transparency on Agios Pharmaceuticals' plans and upcoming catalysts, which may be of interest to investors tracking the company's development.

Insider Trading Filed: 2026-01-07

Tsveta Milanova, the Chief Commercial Officer of Agios Pharmaceuticals, exercised 8,475 restricted stock units and sold 2,872 shares to cover tax withholdings, indicating some insider selling activity.
The transaction was executed pursuant to a 10b5-1 trading plan, suggesting the selling was part of a pre-determined strategy rather than opportunistic.
The remaining 34,793 shares held by Milanova represent her direct beneficial ownership in the company, which could be seen as a sign of her continued commitment to Agios.

Important Information